v3.26.3
Related Party Transactions (Details) - USD ($)
3 Months Ended 12 Months Ended
Jul. 01, 2026
May 26, 2026
Mar. 31, 2026
Sep. 23, 2024
Nov. 13, 2023
Nov. 01, 2019
Sep. 28, 2026
Jun. 30, 2026
Jun. 30, 2025
Related Party Transaction                  
Accounts payable - related parties               $ 7,121 $ 101,417
Research and Development Costs - Related Party               4,707,625 5,549,101
Related party                  
Related Party Transaction                  
Accounts Payable - Related Party               828,577 821,456
Subsequent event                  
Related Party Transaction                  
Payment of clinical trial costs             $ 923,000    
Dr. Anil Diwan | Minimum                  
Related Party Transaction                  
Line of credit       $ 2,000,000          
Maturity of the Company's line of Credit     Mar. 31, 2027 Dec. 31, 2025          
Dr. Anil Diwan | Maximum                  
Related Party Transaction                  
Line of credit       $ 3,000,000          
Maturity of the Company's line of Credit     Dec. 31, 2027 Mar. 31, 2026          
Dr. Anil Diwan | Subsequent event | Minimum                  
Related Party Transaction                  
Maturity of the Company's line of Credit Mar. 31, 2026                
Dr. Anil Diwan | Subsequent event | Maximum                  
Related Party Transaction                  
Maturity of the Company's line of Credit Mar. 31, 2027                
Line of credit agreement | Dr. Anil Diwan                  
Related Party Transaction                  
Line of Credit Facility, maximum borrowing capacity         $ 2,000,000        
Fixed rate of interest on the amount drawn under the line of credit facility         12.00%        
Drew down amount               0  
TheraCour Pharma Inc                  
Related Party Transaction                  
Accounts payable offset by advance               0 0
TheraCour Pharma Inc | Related party                  
Related Party Transaction                  
Accounts Payable - Related Party               828,577 584,089
Accounts payable - related parties                 237,000
Percentage of direct costs           30.00%      
Other general and administrative expense           $ 2,000      
Carrying amount of current accounts payable               237,367  
Percentage of net sales allocated for royalty payments (in percent)           15.00%      
Accrued royalties               0 0
Research and Development Costs - Related Party               1,994,543 2,490,274
KMPL | Related party                  
Related Party Transaction                  
Accounts Payable - Related Party                 237,367
Clinical trial Costs Accrued - Related Party               $ 43,610 9,932
Payment of clinical trial costs   $ 299,130              
Amount of current accounts payable                 $ 237,000